Bausch & Lomb Incorporated
Quick facts
| Founded | 1853 |
|---|
Marketed products
- bepotastine besilate ophthalmic solution
Bepotastine blocks H1 receptors and inhibits histamine release from mast cells. - Brimonidine tartrate ophthalmic solution 0.025%
- bromfenac ophthalmic solution
- Bromfenac Ophthalmic Solution B · Ophthalmology
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. - Dexamethasone 0.1% and tobramycin 0.3%
- fluocinolone acetonide intravitreal implant
- Indomethacin ophthalmic solution
- instillation of NOV03
- Ketorolac Ophthalmic Solution · Ophthalmology
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. - Loteprednol and tobramycin · Metabolic
- Loteprednol etabonate 0.2% · Ophthalmology
Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. - Loteprednol etabonate 0.5% and tobramycin 0.3%
- loteprednol etabonate and tobramycin
- loteprednol etabonate/tobramycin opthalmic suspension · Ophthalmology
Loteprednol etabonate reduces ocular inflammation via glucocorticoid receptor activation, while tobramycin provides broad-spectrum bacterial coverage by inhibiting bacterial protein synthesis. - Lumify® · Ophthalmology
Lumify is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the eye to reduce redness. - Miebo · Ophthalmology
- Olopatadine 0.1% · Ophthalmology/Allergy
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the eye. - pegaptanib sodium injection · Ophthalmology
Pegaptanib sodium is an aptamer that selectively binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. - Perfluorohexyloctane ophthalmic solution
- Soothe® Lubricant Eye Drops · Ophthalmology
Soothe® Lubricant Eye Drops provide ocular surface lubrication and protection by forming a protective film over the cornea and conjunctiva. - Tobramycin and dexamethasone · Ophthalmology
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye. - Tobramycin and dexamethasone ophthalmic suspension · Ophthalmology
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye. - Vehicle of Zylet · Ophthalmology
The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin. - Vitrase · Other
- Zaditor® · Ophthalmology / Allergy
Zaditor is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic responses in the eye.
Phase 3 pipeline
- Azopt 1% · Ophthalmology
Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye. - Bepotastine besilate formulation · Ophthalmology / Allergy
Bepotastine besilate is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms. - BOL-303259-X · Ophthalmology
BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye. - brinzolamide 1% ophthalmic suspension · Ophthalmology
Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye. - Bromfenac Ophthalmic Solution A · Ophthalmology
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. - BTOS-HA · Ophthalmology
BTOS-HA is a hyaluronic acid-based ophthalmic formulation designed to provide sustained lubrication and protection to the ocular surface. - EM-100 · Ophthalmology
EM-100 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation. - Experimental: Vehicle ophthalmic solution · Ophthalmology
A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability. - ISV-403 · Ophthalmology
ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation. - KetoNaph · Ophthalmology
KetoNaph is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain in the eye. - Ketotifen Fumarate 0.035% · Ophthalmology / Allergy
Ketotifen is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic reactions by blocking histamine release and reducing mast cell degranulation. - Ketotifen/naphazoline · Ophthalmology / Allergy
Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while naphazoline is a selective alpha-1 adrenergic agonist, together reducing allergic inflammation and vasoconstriction in the eye. - NOV03 · Infectious Diseases
NOV03 is an investigational antiviral medication. - Prednisolone and Tobramycin · Ophthalmology
This combination uses prednisolone to suppress inflammation and tobramycin to provide topical antimicrobial coverage, typically for ocular infections or inflammatory conditions. - Prednisolones acetate · Ophthalmology
Prednisolone acetate is a corticosteroid that suppresses inflammation and immune responses by inhibiting the production of inflammatory cytokines and mediators. - T-Pred · Ophthalmology
T-Pred is a corticosteroid used to reduce inflammation and suppress the immune system. - Vehicle Gel (BID) · Ophthalmology
Vehicle Gel is a topical ophthalmic gel used to lubricate and protect the eyes. - vehicle of loteprednol etabonate · Ophthalmology
Loteprednol etabonate is a corticosteroid that works by inhibiting the inflammatory response. - Vehicle of Ophthalmic Loteprednol Etabonate · Ophthalmology
Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins. - Vehicle (TID)
Vehicle (TID) is a treatment that does not have a known mechanism of action.
Phase 2 pipeline
- Bepotastine besilate-fluticasone propionate · Ophthalmology
Histamine H1 receptor antagonist and corticosteroid combination - Bepotastine Besilate Nasal Spray 3% Twice a day
- BL1107 High dose · Ophthalmology
BL1107 High dose is an anti-inflammatory agent. - BL1107 Low dose
- BOL-303242-X · Ophthalmology
BOL-303242-X is a small molecule that targets the S1P1 receptor. - bromfenac ophthalmic solution 0.06%
- corticosteroids and immunosuppressants
- Ecabet 2.83%
- Ecabet 3.70% · Gastrointestinal
Ecabet is a gastroprotective agent that acts as a mucosal protective agent. - Loteprednol etabonate suspension
- PF-03187207
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Bausch & Lomb Incorporated
What are Bausch & Lomb Incorporated's marketed drugs?
Top marketed products include bepotastine besilate ophthalmic solution, Brimonidine tartrate ophthalmic solution 0.025%, bromfenac ophthalmic solution, Bromfenac Ophthalmic Solution B, Dexamethasone 0.1% and tobramycin 0.3%, fluocinolone acetonide intravitreal implant.
What is Bausch & Lomb Incorporated's pipeline?
Bausch & Lomb Incorporated has 20 drugs in Phase 3, 11 in Phase 2, 7 in Phase 1. Late-stage candidates include Azopt 1%, Bepotastine besilate formulation, BOL-303259-X, brinzolamide 1% ophthalmic suspension.
When was Bausch & Lomb Incorporated founded?
Bausch & Lomb Incorporated was founded in 1853.
How many employees does Bausch & Lomb Incorporated have?
Bausch & Lomb Incorporated has approximately 12,900 employees.